For some of these genes, like PTPRT [37, 38], PTPRD [38], ERBB4 [39], ATRX [40], TERT [41], POLE [8], NTRK3 [42], EPHA5 [43], and ALK [14], previous literature has highlighted their potential roles as biomarkers for ICIs therapy in NSCLC. This evidence concerns the gene EPHA5 and non-small cell lung carcinoma.